#5 - Bluebird Bio (NASDAQ:BLUE)
Bluebird Bio (NASDAQ: BLUE) - Another Cambridge, Massachusetts makes the list. Like Alnylam, Bluebird specializes in the area of gene therapy. In the case of Bluebird, they are focusing on applications for neurological disorders. The problem that investors are mulling over with Bluebird is the competitive landscape around its most promising drugs. In the pharmaceutical space, the window of exclusivity is very narrow and the space for Bluebird continues to be very crowded. Having said that, Bluebird also has valuation concerns. Their 2017 revenue was just under $40 million however its market value was $10.5 billion for a price/revenue ratio of 272. After the stock reached a record high of $236.17 in March of 2018, it has steadily retreated and is now selling around $119. The stock still has a market cap of $6.51 billion. If investors are looking for a positive sign, it's that Bluebird's pipeline is loaded. If only a few of these drugs take off, it could make the stock a buying opportunity. However, for now, the better play may be to let this one fly away.
About bluebird bio
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Read More - Current Price
- $8.50
- Consensus Rating
- Hold
- Ratings Breakdown
- 2 Buy Ratings, 6 Hold Ratings, 2 Sell Ratings.
- Consensus Price Target
- $49.14 (478.2% Upside)
